Travere Therapeutics’ Filspari (sparsentan) became the first fully FDA-approved treatment for focal segmental glomerulosclerosis (FSGS). The approval expands the company’s label beyond accelerated approval previously granted for IgA nephropathy and includes pediatric and adult populations meeting specific criteria. Multiple reports tied the approval to regulatory support for proteinuria as a surrogate endpoint, aligning with how nephrology trials are evaluated when clinical endpoints take longer to mature. The milestone also adds a second revenue opportunity beyond the company’s existing rare-kidney franchise.